The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.

To achieve the goals set out in its 'Vision 2030', argenx has set the following priorities for 2025: VYVGART® (IV: efgartigimod alfa ... Phase 2 studies across efgartigimod, empasiprubart and ARGX-119 ...

If you want a laptop and like the idea of having one that can double as a tablet, you need one of the best 2-in-1 laptops on the market. There are a lot of options to choose from, but a few rise ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision T cell activation, today announced that Zhen Su, M.D., MBA, the Company's Chief Executive ...

Nemvaleukin alfa (nemvaleukin) is an engineered fusion protein designed to leverage IL-2's antitumor effects while mitigating the hallmark toxicities that limit its use. Nemvaleukin selectively binds ...

That said, due to the current flaccid demand from retail customers for electric cars, Alfa will also bring a petrol Ibrida (that’s Italian for hybrid) version to the UK in mid-2025 ...